Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and feasibility of combination
chemotherapy with target agents according to the result of targeted deep sequencing in
pediatric patients with relapsed/refractory solid tumor or AML.
Phase:
Phase 2
Details
Lead Sponsor:
Samsung Medical Center
Collaborators:
Ministry of health & welfare, Republic of Korea Ministry of Health, Republic of Korea